


PHARMACEUTICAL 2022

Molecular Templates Inc. Rank 283 of 475





PHARMACEUTICAL 2022

Molecular Templates Inc. Rank 283 of 475

The relative strengths and weaknesses of Molecular Templates Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Molecular Templates Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 105% points. The greatest weakness of Molecular Templates Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is -166%, being 110% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	148,215
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	46,670
Liabilities, Non-Current	46,680
Other Assets	24,838
Other Compr. Net Income	-65
Other Expenses	3,369
Other Liabilities	33,350
Other Net Income	39,131
Property and Equipment	19,309
Research and Development	84,665
Revenues	0
Selling, General and Administrative Expense	34,106

Output Variable	Value in 1000 USD
Assets	192,362
Liabilities	126,700
Expenses	122,140
Stockholders Equity	65,662
Net Income	-83,009
Comprehensive Net Income	-83,042
Economic Capital Ratio	-166%